Skip to Content
Stock Strategist

Aptar's Niche Focus Delivers Profits

Pharma dispensing systems and excellent management have brought success.


We found  AptarGroup's (ATR) fourth-quarter results to be lackluster, particularly in the beauty and home as well as the food and beverage segments, both of which posted declining year-over-year core sales and lower margins. Beauty and home has struggled in recent years as tepid U.S. consumer spending has weighed on volume, but we also think Aptar lacks durable competitive advantages in this business. We're pleased to see the company has changed the segment's management team and plans to make operations more efficient. After a stellar third quarter, food and beverage segment sales to the beverage market decreased 16% year over year as a result of inventory destocking and soft demand in Asia and the United States. Over the next five years, we expect beverage sales to grow in the low double digits annually on average.

The more important pharma segment turned in another solid quarter, with 6% year-over-year core sales growth and a 120-basis-point operating margin improvement to 27.5%. We were particularly pleased with the recovery in the injectables market following inventory destocking by customers in recent quarters. Now that GlaxoSmithKline's Flonase allergy treatment is being sold over the counter in the U.S., Aptar should benefit from higher volume because it supplies the product's delivery device.

Todd Wenning does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.